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2,2-dimethylpentanedioic acid (2dmepdaH2) and 3,3-dimethylpentanedioic acid (3dmepdaH2) reacted with copper(II) acetate to
give [Cu(2dmepda)(H2O)3]2 (1) and [Cu(3dmepda)(H2O)3]2 (2). Reaction of (1) and (2) with 1,10-phenanthroline and 2,2 -bi-
pyridine yielded [Cu(2dmepda)(phen)(H2O)]20.5phen (3), [Cu(2dmepda)(bipy)(H2O)]2 (4), [Cu(2dmepda)(bipy)(Et−
OH)]2 ·2EtOH (4A), [Cu(3dmepda)(phen)(H2O)]2 (5), and [Cu(3dmepda)(bipy)(H2O)]2 ·(6). The structures of (4A) and (6)
each consists of a [Cu(bipy)(dicarboxylate)(solvent)]2 dimer. The superoxide dismutase (SOD) mimetic activity of the novel cop-
per complexes and their manganese analogues was investigated. The dimethyl sulphoxide(DMSO) soluble complexes (1)–(4)a n d
(6) were assessed for their cancer chemotherapeutic potential towards hepatocellular carcinoma and kidney adenocarcinoma cell
lines. The 1,10-phenanthroline containing complex [Cu(2dmepda)(phen)(H2O)]20.5phen (3) was the most potent with activity
that compares well to that of cisplatin.
Copyright © 2006 Michael Devereux et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
A range of monocarboxylic acids are known to have a variety
of pharmacological eﬀects. Salicylic acid and its derivatives,
for example, have been shown to possess anti-inﬂammatory
and antitumour activity [1]. Upon coordination to a suitable
metal centre, the biologically active carboxylic acids often
become more eﬀective and desirable drugs [2]. The carboxy-
late group is an important class of ligand in inorganic and
bioinorganic chemistry, metal complexes containing mono-
carboxylicacidsarewellknown,andthepublicationofmany
structurally characterised examples of this class of com-
pound has demonstrated its versatility as an inner-sphere
ligand [3]. The coordination chemistry of dicarboxylic acids
is far less developed as polymeric products are usually ob-
tained, and indeed structural information for this class of
complex is relatively scarce. Recently, we have shown that the
reaction of polymeric dicarboxylate complexes of copper(II),
manganese(II), and cobalt(II) with the N,N-donor ligands
1,10-phenanthroline and 2,2 -bipyridine can lead to the
synthesis of crystalline compounds which are easily struc-
turally characterised by X-ray methods [4–9]. A number
of the manganese complexes have been found to exhibit
excellent catalase-mimetic activity [5, 8] and it has also been
demonstrated that N-donor derivatives of the dicarboxylate
c o m p l e x e so far a n g eo fm e t a l sa r ev e r ye ﬀective antifungal
agents possessing signiﬁcantly diﬀerent modes of action to
the state-of-the-art prescription drugs [10–12].2 Bioinorganic Chemistry and Applications
As part of our ongoing studies into the synthesis, biom-
imetic, and biological applications of novel transition metal
carboxylate complexes, we report here the properties and
structures for copper(II) complexes of 2,2-dimethylpentan-
edioic acid and 3,3-dimethylpentanedioic acid. The ability of
thecoppercomplexestodismutatesuperoxidehasbeencom-
pared to manganese(II) analogues we have previously pub-
lished [9]. The chemotherapeutic potentials of several of the
novel copper complexes towards two tumourigenic model
cell lines are also discussed.
EXPERIMENTS
Chemistry
Chemicals were purchased from commercial sources and
used without further puriﬁcation. IR spectra were recorded
in the region 4000–400cm−1 on a Nicolet-400 Impact spec-
trometer. Magnetic susceptibility measurements were made
using a Johnson Matthey magnetic susceptibility balance.
[HgCo(SCN)4] was used as a reference. Satisfactory micro-
analyticaldataforthecomplexeswerereportedbytheMicro-
analytical Laboratory, University College Cork, Ireland. The
manganese complexes were synthesised using a method pre-
viously published [9].
[Cu(2dmepda)(H2O)3]2 (1)
To a solution of 2,2-dimethylpentanedioic acid (2dme−
pdaH2) (1.615g, 0.01 moles) in H2O (100cm3)w a sa d d e d
[Cu2(CH3CO2)4 ·2H2O] (4.05g, 0.001 moles) and the re-
sulting green mixture was reﬂuxed for 2 hours. Upon cool-
ing, the green solid which deposited was ﬁltered oﬀ, washed
with two portions of distilled H2O, and dried in vacuo.
Yield: 2.21g (82.86%); calc %: C 30.47 H 5.85; found %: C
30.94 H 5.73; IR(KBr): 3423, 2963, 2919, 1597, 1477, 1421,
1373, 1305, 1241, 1173, 1148, 1053, 824, 784, 724, 684, 636,
462cm−1.μeﬀ = 1.86BM;solubility:insolubleinwater,solu-
bleinethanol,andpartiallysolubleinmethanolandacetone.
[Cu(3dmepda)(H2O)3]2 (2)
To a solution of 3,3-dimethylpentanedioic acid (3dme−
pdaH2) (1.60, 0.01 moles) in distilled H2O (100cm3)w a s
added [Cu2(CH3CO2)4 · 2H2O] (4.05g, 0.01 moles) and the
resulting green mixture was reﬂuxed for 2 hours. Upon cool-
ing, the green solid which deposited was ﬁltered oﬀ, washed
withtwoportionsofdistilledH2O,anddriedinvacuo.Yield:
1.88g (75.91%); calc %: C 30.49 H 4.85; found %: C 30.82
H 5.10; IR(KBr): 3652, 3423, 2951, 1605, 1405, 1317, 1277,
1248, 1176, 1161, 904, 804, 768, 732, 676, 624, 468cm−1.
μeﬀ = 1.61BM;solubility:insolubleinwaterandacetoneand
partially soluble in heated ethanol and methanol.
[Cu(2dmepda)(phen)(H2O)]2 ·0.5phen(3)
To a solution of [Cu(2dmepda)(H2O)3]2 (1) (0.75g, 0.0015
moles), in ethanol (50cm3), was added 1,10-phenanthroline
(2.48g, 0.0136 moles) and the mixture was reﬂuxed for two
hours. The resulting dark green solution was concentrated
to approximately 5cm3 and acetone (10cm3)w a sa d d e da n d
after several days at room temperature, a blue solid precip-
itated. The product was ﬁltered oﬀ, washed with a small
volume of ethanol, and then dried in vacuo. Yield: 1.02g
(76.66%); calc %: C 58.87 H 4.74, N 8.24; found %: C 58.55
H 4.66 N 8.10; IR(KBr): 3399, 3055, 2959, 2915, 2859, 1561,
1517, 1469, 1425, 1397, 1365, 1297, 1225, 1145, 1105, 857,
720, 648cm−1. μeﬀ = 1.92BM; solubility: soluble in water,
ethanol and methanol. Insoluble in acetone.
[Cu(2dmepda)(bipy)(H2O)]2 (4)
To a solution of [Cu(2dmepda)(H2O)3]2 (1) (0.75g, 0.0015
moles), in ethanol (50cm3) was added 2,2 -bipyridine
(2.12g, 0.0136 moles) and the resulting dark green solution
was reﬂuxed for 2 hours. Upon standing for several days at
room temperature, a blue powder precipitated, was ﬁltered,
washed with a small portion of methanol and acetone, and
then placed in an oven to dry. Yield: 0.98g (72.90%); calc %:
C 51.57 H 5.09 N 7.08; found %: C 51.07 H 4.93 N 7.07;
IR: 3451, 3111, 3079, 2963, 2923, 2875, 1569, 1477, 1445,
1401, 1365, 1309, 1237, 1157, 1057, 1034, 905, 836, 776, 728,
640cm−1. μeﬀ = 2.12; solubility: insoluble in water, ethanol
and acetone, soluble in methanol.
Upon standing for several weeks, the ﬁltrate yielded a
small quantity of crystals of [Cu(2dmepda)(bipy)(EtOH)]2·
2EtOH (4A) which were suitable for X-ray analysis.
[Cu(3dmepda)(phen)(H2O)]2 (5)
To a solution of [Cu(3dmepda)(H2O)3]2 (2) (0.52g, .00103
moles) in ethanol (50cm3) was added 1,10–phenanthroline
(1.64g, 0.0092 moles) and the resulting dark brown solution
was reﬂuxed for two hours. The solution was then cooled
and concentrated to 5cm3 and acetone (15cm3)w a sa d d e d
precipitating a green solid which was ﬁltered oﬀ, washed
with a small volume of ethanol, and dried in vacuo. Yield:
0.22g (30.91%); calc %: C 58.87 H 4.74 N 8.24; found %: C
58.96H4.56N8.94%;IR(KBr):3395,1557,1517,1425,1381,
1305, 1253, 1225, 1145, 1105, 849,776, 724cm−1. μeﬀ = 1.98;
solubility: insoluble in water, ethanol, and acetone. Soluble
in methanol.
[Cu(3dmepda)(bipy)(H2O)]2 ·(6)
To a solution of [Cu(3dmepda)(H2O)3]2 (2) (0.51g, 0.00101
moles) in ethanol (50cm3), was added 2,2 -bipyridine
(1.44g, 0.0092 moles) and the resulting dark brown solu-
tion was reﬂuxed for 2 hours. The solution was then cooled
and concentrated to 5cm3 and acetone (15cm3)w a sa d d e d
precipitating a blue solid which was ﬁltered oﬀ, washed with
a small volume of ethanol, and dried in vacuo. Yield: 0.21g
(32.34%); calc %: C 51.57 H 5.09 N 7.08; found %: C 52.33
H 4.87 N 7.27; IR(KBr): IR: 3399, 3055, 2959, 2915, 2859,
1561, 1517, 1469, 1425, 1397, 1365, 1297, 1225, 1145, 1105,
857, 720, 648cm−1. μeﬀ = 2.22; solubility: insoluble in water,
ethanol, and acetone.Michael Devereux et al 3
Table 1: Crystal data and structure reﬁnement for [Cu(2dmepda)(bipy)(EtOH)]2 ·2EtOH (4A) and [Cu(3dmepda)(bipy)(H2O)]2 ·6H2O
(6).
Empirical formula C34H54Cu2N4O16 C42H60Cu2N4O12
Formula weight 449.94 470.01
Temperature 153(2)K 153(2)K
Wavelength 0.71073 ˚ A 0.71073 ˚ A
Crystal system Monoclinic Triclinic
Space group P2(1)/c P-1
Unit-cell
dimensions
a = 11.083(3) ˚ A; α = 90◦ a = 9.2092(17) ˚ A; α = 106.374(12)◦
b = 15.343(4) ˚ A; β = 96.85(2)◦ b = 11.046(2) ˚ A; β = 105.160(13)◦
c = 12.195(3) ˚ A; γ = 90◦ c = 12.2098(18) ˚ A; γ = 101.568(13)◦
Volume 2058.9(10) ˚ A3 1098.6(3) ˚ A3
Z2 1
Density (calculated) 1.452Mg/m3 1.421Mg/m3
Absorption coeﬃcient 1.106mm−1 1.033mm−1
F(000) 940 494
Crystal size 0.32 ×0.42 ×0.32mm3 0.50 ×0.46 ×0.36mm3
Theta range for data collection 2.14 to 25.00◦ 2.01 to 25.00◦
Index ranges 0 ≤ h ≤ 13, −18 ≤ k ≤ 1, −14 ≤ l ≤ 14 −10 ≤ h ≤ 0, −12 ≤ k ≤ 12, −14 ≤ l ≤ 14
Reﬂections collected 4145 4044
Independent reﬂections 3633 [R(int) = 0.0192] 3780 [R(int) = 0.0127]
Completeness to theta = 25.00◦ 99.9% 97.8%
Absorption correction Empirical Empirical
Max and min transmission 0.7975 and 0.7547 0.8507 and 0.6635
Reﬁnement method Full-matrix least-squares on F2 Full-matrix least-squares on F2
Data/restraints/parameters 363/0/253 3780/0/271
Goodness-of-ﬁt on F2 1.025 1.072
Final R indices [I > 2sigma(I)] R1 = 0.0365, wR2 = 0.0719 R1 = 0.0311, wR2 = 0.0733
R indices (all data) R1 = 0.0608, wR2 = 0.0795 R1 = 0.0387, wR2 = 0.0764
Largest diﬀ peak and hole 0.292 and −0.309e·˚ A−3 0.526 and −0.314e·˚ A−3
Upon standing for several weeks, the ﬁltrate yielded a
small quantity of crystals of [Cu(3dmepda)(bipy)(H2O)]2·
6H2O which were suitable for X-ray analysis.
X-rayCrystallography
Both data sets were collected at 153(2)K using a Siemens
P4 diﬀractometer with Mo-Kα radiation (λ = 0.71073 ˚ A,
2θmax = 25.0◦) and corrected for Lorentz, polarisation, and
absorption eﬀects. The structure for (4A) was solved by di-
rect methods and (6) was solved using a Patterson map. Both
structureswerereﬁnedbyfull-matrixleast-squaresonF2,us-
ing all the reﬂections; the non-hydrogen atoms were reﬁned
withanisotropicatomicdisplacementparametersandhydro-
gen atoms bonded to carbon atoms were inserted at calcu-
lated positions. Hydrogen atoms bonded to oxygen were lo-
cated from diﬀerence Fourier maps and not further reﬁned.
There were no signiﬁcant residual peaks in either electron
density map. Details of the collection and reﬁnement are
given in Table 1. All programs used in the structure solution
and reﬁnement are contained in the SHELXTL package [13].
Superoxidedismutaseactivity
The O2
•− dismutase activities of the metal complexes were
assessed using a modiﬁed NBT assay with xanthine-xanthine
oxidase system as the source of O2
•− [14]. All reagents were
obtained from Sigma-Aldrich Chemical Co Ltd and assays
were run in 3mL of solution. Results are graphed as the in-
hibition % of NBT reduction for three concentrations. Tabu-
lated results were derived from linear regression analyses and
are given as the concentration (μM) equivalent to 1U bovine
erythrocyte superoxide dismutase (SOD).
Cytotoxiciytesting
Dimethyl sulphoxide (DMSO) and all cell culture reagents
and media were purchased from Sigma-Aldrich Ireland, Ltd,
unless otherwise stated.
Cytotoxicity assays were performed using two human
malignant model cell lines in order to assess the cancer
chemotherapeutic potential of the Cu complexes of 2,2- and
3,3-dimethylpentanedioic acid. Hepatocellular carcinoma
(HepG2) and kidney adenocarcinoma (A-496) cell lines were
purchased from the ATCC. All cell lines were grown as mon-
olayersinEagle’sminimumessentialmedium,supplemented
with 2mM L-glutamine and Earle’s balanced salt solution,
containing 1.5gdm−3 sodium bicarbonate, 0.1mM nones-
sential amino acids, 1.0mM sodium pyruvate, 100Ucm−3
penicillin, and 100μgcm −3 streptomycin supplemented to
contain 10% (v/v) foetal bovine serum (Flow laboratories,
Herts, UK). All cells were grown at 37◦C in a humidiﬁed
atmosphere, in the presence of 5% CO2 a n dw e r ei nt h e
exponentialphaseofgrowthatthetimeofassay.Cytotoxicity
was assessed using MTT assay. Each of the two cell lines
(100μL) were seeded at a density of 5×104 cells cm−3 into
sterile 96 well ﬂat-bottomed plates (Falcon Plastics, Becton4 Bioinorganic Chemistry and Applications
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Scheme 1: Synthetic routes to the complexes (1)–(6).
Dickinson) and grown in 5% CO2 at 37◦C. Test compounds
were dissolved in DMSO and diluted with culture media.
The maximum percentage of DMSO present in all wells
was 0.2% (v/v). Each drug solution (100μL) was added to
replicate wells in the concentration range of 0.1–1000μM
and incubated for 96 hours. A miniaturised viability assay
using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide (MTT) was carried out according to the method
described by Mosmann [15]. The IC50 value, deﬁned as
the drug concentration causing a 50% reduction in cellular
viability, was calculated for each drug. Each assay was carried
out using ﬁve replicates and repeated on at least three
separate occasions. Viability was calculated as a percentage
of solvent-treated control cells, and expressed as a percentage
of the control. The signiﬁcance of any reduction in cellular
viability was determined using one-way ANOVA (analysis
of variance). A probability of 0.05 or less was deemed sta-
tistically signiﬁcant.
RESULTS AND DISCUSSION
Synthetic routes to the complexes (1)–(6) are shown in
Scheme 1. Reaction of either 2,2-dimethylpentanedioic acid
(2dmepdaH2) or 3,3-dimethylpentanedioic acid (3dme−
pdaH2) with copper(II) acetate gave the complexes [Cu(2−
dmepda)(H2O)3]2 (1) and [Cu(3dmepda)(H2O)3]2 (2), re-
spectively. Reaction of (1) with either 1,10-phenanthroline
or 2,2 -bipyridine resulted in the synthesis of [Cu(2dme−
pda)(phen)(H2O)]2 ·0.5phen (3), [Cu(2dmepda)(bipy)−
(H2O)]2 (4), and [Cu(2dmepda)(bipy)(EtOH)]2 · 2EtOH
(4A). [Cu(3dmepda)(phen)(H2O)]2 (5)a n d[ C u ( 3 d m e −
pda)(bipy)(H2O)]2 · (6) were obtained when (2)w a st r e a t e d
similarly.
Crystals of the hepta hydrate of (6) {[Cu(3dme−
pda)(bipy)(H2O)]2 · 6H2O} were obtained from the mother
liquor by slow evaporation.
The X-ray crystal structures of [Cu(2dmepda)(bipy)−
(EtOH)]2 · 2EtOH (4A) and [Cu(3dmepda)(bipy)(H2O)]2·
6H2O( 6) are shown in Figures 1 and 2 and selected bond
lengths and angles are listed in Tables 2 and 3,r e s p e c t i v e l y .
The two structures are closely related, each consisting
of a [Cu(bipy)(dicarboxylate)(solvent)]2 dimer located on
a centre of symmetry. The copper ions are ﬁve-coordinate
and have approximately square pyramidal geometry with the
coordinated solvent as the apical donor (ethanol and wa-
ter for (4A)a n d( 6), resp). The donors in the basal planeMichael Devereux et al 5
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Figure 1: The structure of dimeric [Cu(2dmepda)(bipy)(EtOH)]2 ·2EtOH (4A).
O1W
N2
N1
Cu
O22
O21
O23A
O24A O21A
O22A
N1A
N2A
CuA
O1WA
O24
O23
Figure 2: The dimeric structure of [Cu(3dmepda)(bipy)(H2O)]2 ·(6)( c r y s t a l so f( 6) were obtained as the hepta hydrate. The six water
molecules of crystalisation have been omitted for clarity).
Table 2: Bond lengths (˚ A) and angles (◦) for [Cu(2dmepda)−
(bipy)(EtOH)]2 ·2EtOH (4A).
Cu−O(21) 1.955(2)
Cu−O(23∗) 1.9836(19)
Cu−N(1) 2.010(2)
Cu−N(2) 2.003(2)
Cu−O(1W) 2.307(2)
O(21)−Cu−O(23∗) 90.22(8)
O(21)−Cu−N(2) 92.99(9)
O(23∗)−Cu−N(2) 165.11(9)
O(21)−Cu−N(1) 173.23(9)
O(23∗)−Cu−N(1) 95.09(9)
N(2)−Cu−N(1) 80.82(10)
O(21)−Cu−O(1W) 95.60(8)
O(23∗)−Cu−O(1W) 99.71(8)
N(2)−Cu−O(1W) 94.45(9)
N(1)−Cu−O(1W) 87.66(8)
Symmetry transformations used to generate equivalent atoms: ∗3 −x, −y,
2 −z, †1 −x,1− y,1−z.
comprise the two bipyridine nitrogen atoms and two car-
boxylate oxygen atoms, one from each of two dicarboxy-
late ligands. The apical ligand forms a hydrogen bond to
Table 3: Bond lengths (˚ A) and angles (◦) for [Cu(3dmepda)−
(bipy)(H2O)]2 ·6H2O( 6).
Cu−O(21) 1.9376(17)
Cu−O(23†) 1.9452(16)
Cu−N(1) 2.0116(19)
Cu−N(2) 2.0165(19)
Cu−O(30) 2.4119(18)
O(21)−Cu−O(23†) 92.09(7)
O(21)−Cu−N(1) 169.65(7)
O(23†)−Cu−N(1) 93.50(7)
O(21)−Cu−N(2) 93.31(8)
O(23†)−Cu−N(2) 172.23(7)
N(1)−Cu−N(2) 80.34(8)
O(21)−Cu−O(30) 97.17(7)
O(23†)−Cu−O(30) 90.13(7)
N(1)−Cu−O(30) 91.52(7)
N(2)−Cu−O(30) 94.73(7)
Symmetry transformations used to generate equivalent atoms: ∗3 −x, −y,
2 −z, †1 −x,1− y,1−z.
the uncoordinated oxygen of one of the dicarboxylate groups
{O(30)−O(22) 2.595(3) ˚ Aa n dO ( 1 w ) −O(22) 2.644(3) ˚ Ai n
(4A)a n d( 6), resp} (Figures 3 and 4). The two copper ions6 Bioinorganic Chemistry and Applications
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Figure 3: The hydrogen bonding in [Cu(2dmepda)(bipy)(EtOH)]2 ·2EtOH (4A).
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Figure 4: The hydrogen bonding in [Cu(3dmepda)(bipy)(H2O)]2 ·(6).
in the dimeric unit are therefore linked by two dicarboxylate
groups.
The uncoordinated ethanol molecule in (4A)i sh y d r o -
gen-bondedtotheseconduncoordinatedcarboxylateoxygen
{O(40)−O(24)2.808(3) ˚ A}(Figure 3);therearenootherhy-
drogen atoms available for further hydrogen bonding. The
moleculesarelinkedintochainsbyπ-π bondingbetweenthe
bipyridine ligands (Figure 5) on neighbouring molecules on
the opposite side of the copper to the coordinated ethanol
molecule (interplanar distance approximately 3.6 ˚ A). Inter-
action on the opposite plane is prevented by the apical lig-
and.
There are three uncoordinated water molecules in the
asymmetric unit of (6) (six per dimer) and these are all
involved in hydrogen bonding to the carboxylates, the co-
ordinated water, and each other (Figure 6). These hydrogen
bonds extend through the lattice and there is also some weak
π-π interaction between each bipyridine ring and one neigh-
bouring ring from another dimmer on the same side as the
coordinated water molecule (interplanar distance ca 3.6 ˚ A).
As was the case for (4A)a n d( 6), the IR spectra of com-
plexes (1)–(3)a n d( 5) all contain prominent νasym(COO)
stretching bands in the region 1550–1610cm−1 and
νasym(COO) stretching bands in the region 1400–1390cm−1
[Δν(COO) = 164–200cm−1]. The Δν(COO) values suggest
that the coordination modes of the dicarboxylate ligands in
these complexes may be similar to those found in (4A)a n d
(6)[ 16].Michael Devereux et al 7
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Figure 5: The packing diagram for [Cu(2dmepda)(bipy)(EtOH)]2 ·2EtOH (4A) showing the π-π stacking.
O
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c
Figure 6: The packing diagram for [Cu(3dmepda)(bipy)(H2O)]2 ·6H2O( 6) showing the π-π stacking.8 Bioinorganic Chemistry and Applications
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Figure 7: SOD activity proﬁles of compounds (1)–(11) as assessed by the NBT assay.
The room-temperature magnetic moments of powdered
samplesofcomplexes(1)–(6)(μeﬀ = 1.61–2.22BM)arecon-
sistent for copper(II) complexes where there are no signif-
icant exchange interactions between adjacent metal centres
[17]. As was the case for (4A)a n d( 6)c o m p l e x e s ,( 1)–(3)
and (5) were found to be quite soluble suggesting that they
are not polymeric supporting their formulation as dimeric
complexes. The inclusion of 0.5 molecules of phen of crys-
tallisation in (3) is not unusual as complexes incorporating
similar ligands as uncoordinated molecules have been previ-
ously structurally characterised and reported by this group
[18].
SODactivity
Since the discovery of the functionality of the enzyme SOD
[19], intensive eﬀorts have been made to develop the enzyme
as a therapeutic agent for the treatment of diseases such
as rheumatoid arthritis and osteoarthritis, conditions which
are associated with oxidative stress [20]. For several reasons,
such as the size and instability of the SOD enzyme, these at-
tempts to develop the natural enzyme for clinical use have
been largely unsuccessful. A great deal of of interest has been
shown in the development of therapeutic SOD mimetics for
the scavenging of superoxide(O2
•−)w h i c hi sap r e c u r s o rt o
reactive oxygen and nitrogen species(RONS) known to con-
tribute to oxidative stress [21].
Recently, Cu(II) and Mn(II) complexes of the polycar-
boxylate EDTA and related chelators have been shown to ex-
hibitsigniﬁcantSODmimeticactivities(usingamodiﬁedni-
trobluetetrazolium (NBT) assay) [22, 23]. The SOD mimetic
activitiesofthecopper(II)complexes(1)–(6)andﬁveoftheir
manganese(II) analogues (complexes (7)–(11)—previously
published [9]) were determined. The results are given in
Figure 7 and Table 4 as concentrations equivalent to one unit
of bovine erythrocyte SOD. Signiﬁcant activities were seen
for all compounds tested with one unit of SOD activity aris-
ing from the range of 0.37 to 0.96μM aqueous solutions. The
copper complexes (1)–(3)a n d( 5)–(6) are the most active
comparingfavourablywithanumberofsyntheticSODmim-
ics developed for therapeutic purposes [21].
Anticancerstudies
We have recently shown that transition metal complexes of
selected carboxylate and dicarboxylate ligands exhibit sig-
niﬁcant in vitro anticancer activity [12, 24]. The ability of
the DMSO soluble copper complexes (1)–(4)a n d( 6) to kill
human-derived cancer cells was investigated using HepG2
and A-498 cells and a standard bioassay, MTT. Cells were
continuously exposed to test agent for 96 hours, and their ef-
fects on cellular viability was evaluated. It was intended that
the results from these studies would allow the identiﬁcation
of those derivatives with cancer chemotherapeutic potential.
Therefore, proﬁles of cell viability against complex concen-
tration were established (Figures 8 and 9)a n dw e r eu s e dt o
calculate the IC50 values for each derivative (Table 5). Com-
parison of IC50 values allowed the relative potency of each of
the test compounds to be determined and ranked.
All ﬁve compounds screened displayed a concentration-
dependent cytotoxic proﬁle across the two cell lines stud-
ied here. The order of the observed cytotoxicity was seen asMichael Devereux et al 9
Table 4: SOD activity proﬁles of compounds (1)–(11) as assessed by the NBT assay.
Compound Complex Concentration (μM) equivalent to 1U SOD
(1) [Cu(2dmepda)(H2O)3]2 0.51
(2) [Cu(3dmepda)(H2O)3]2 0.52
(3) [Cu(2dmepda)(phen)(H2O)]2 ·0.5phen 0.46
(4) [Cu(2dmepda)(bipy)(EtOH)]2 ·2EtOH 0.88
(5) [Cu(3dmepda)(phen)(H2O)]2 0.38
(6) [Cu(3dmepda)(bipy)(H2O)]2 ·6H2O0 . 3 7
(7) [Mn(2dmepda)] ·1.5H2O0 . 8 3
(8) [Mn(3dmepda)] ·H2O0 . 7 7
(9) [Mn(2dmepda)(phen)2]0 . 8 9
(10)[ M n 2(2dmepda)2(bipy)3] ·H2O0 . 6 8
(11) [Mn(3dmepda)(phen)2] ·7.25H2O0 . 9 6
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Figure 8:Eﬀectsof(1)–(4),(6),andphenontheviabilityofHepG2
cells (human hepatocellular), following continuous incubation for
96 hours, with increasing drug concentration (0.1–500μM). Bars
indicate standard error of the mean (SEM) and results were statis-
tically signiﬁcant from control at P<. 05. Results are representative
of three independent experiments (n = 3).
(3) > (4) > (6) > (2) > (1), with (3) appearing as the most
potent and (1) as the least potent. The results presented
in Table 5 also illustrate that the free Cu salt was inca-
pable of eliciting a cytotoxic response. The inclusion of
the N,N-donor ligands 1,10-phenanthroline(phen) and 2,2 -
bipyridine(bipy) in the simple Cu(II) complexes of the 2,2-
and 3,3-dimethylpentanedioic acids signiﬁcantly increased
the potency of the system. However, it is also notewor-
thy that the metal-free phenanthroline is itself signiﬁcantly
cytotoxic and that the best copper complex containing it (3)
isapproximately3and2times morepotentfortherespective
cell lines. Complex (3) was capable of killing both cancer-
derived cell lines at very low concentrations with IC50 val-
ues of 1.70 and 1.55μM (equivalent to 1.49 and 1.37μg/mL),
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Figure 9: (1)–(4), (6), and phen on the viability of A-498 cells (hu-
man renal cell carcinoma), following continuous incubation for 96
hours, with increasing drug concentration (0.1–500μM). Bars in-
dicate standard error of the mean (SEM) and results were statisti-
cally signiﬁcant from control at P<. 05. Results are representative
of three independent experiments (n = 3).
for the liver and kidney cell lines, respectively. The activity of
(3) falls well within the accepted activity parameters adopted
for in vitro screening of potential chemotherapeutic drugs
[25]. Furthermore, the IC50 values for (3) are comparable to
those of the clinically used drug cis platin [26]. The relatively
unique structure found in this class of compound may serve
to provide a lead structure for the development of further
compounds with an even greater cancer chemotherapeutic
potential.
SUPPLEMENTARY MATERIAL
Crystallographic data have been deposited with the CCDC
(12UnionRoad,Cambridge,CB21EZ,UK)andareavailable10 Bioinorganic Chemistry and Applications
Table 5: Cancer chemotherapeutic potential of (1)–(6), phen, and the free copper salt was determined in HepG2 and A-498 cells, following
continuous incubation for 96 hours in the concentration range of 0.1–500μM, using MTT assay. A graph of viability as % of solvent-
treated control versus drug concentration was used to calculate IC50 values (μM), (mean ± SEM; n = 5). Results are representative of three
independent experiments (n = 3).
Complex HepG2 A-498
IC50(μM) Mean ± S.E.M. IC50 (μM) Mean ± S.E.M.
[Cu(2dmepda)(H2O)3]2 (1) 389.00 ±20.00 110.00 ±51.32
[Cu(3dmepda)(H2O)3]2 (2) 180.00 ±50.35 95.00 ±10.00
[Cu(2dmepda)(phen)(H2O)]2 ·0.5phen (3)1 .70 ±0.08 1.55 ±0.08
[Cu(2dmepda)(bipy)(EtOH)]2 ·2EtOH (4)1 5 .00 ±2.31 9.50 ±1.81
[Cu(3dmepda)(bipy)(H2O)]2 ·6H2O( 6)2 6 .00 ±6.05 15.50 ±6.67
Phen 5.80 ±0.31 4.1 ±0.54
Cu salt {Cu(ClO4)2 ·6H2O} > 1000.00 ±1.00 973.30 ±26.67
on request quoting the deposition numbers CCDC238512
and CCDC238511, respectively.
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